Founded in 1992, medicine is its flagship product, and its Jinshuibao Capsule, Xingnaojing Injection, and Kanglaite Injection are well-known in the industry
Founded in Beijing in 1992 and formally established in 2000, Jemincare Group is a comprehensive health industry group integrating "industry, capital, management and resources" on the Internet.Since its establishment more than ten years ago, the group has adhered to the corporate strategy of combining connotative growth, epitaxial expansion and integrated development, and has successively participated in the holding of Jiangxi Jemincare Jinshuibao Pharmaceutical Co., Ltd., Jiangxi Jemincare Pharmaceutical Co., Ltd., Wuxi Jemincare Shanhe Pharmaceutical Co., Ltd., Jiangxi Sinopharm Co., Ltd., Zhejiang Kanglaite Pharmaceutical Co., Ltd., Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd., Beijing Zhengda Luzhou Pharmaceutical Co., Ltd., in Jiangxi, Beijing, Jiangsu, Zhejiang, Hong Kong, the United States, There are subsidiaries in Australia and other places, sales branches cover the whole country, and the products are exported to Southeast Asia, Europe and the United States.
While the scale continues to grow, Jemincare Group focuses on cultivating fist varieties, including "Jinshuibao Capsule", which has the largest market share of prescription drug tonic and nephrology Chinese patent medicine in China, "Xingnaojing Injection", a national emergency drug "Xingnaojing Injection", a traditional Chinese medicine injection "Kanglaite" injection with "biphasic broad-spectrum anti-cancer effect", a national Class 1.1 new drug "Xineng" (etimicin sulfate injection) and a number of national first-class new drugs and confidential varieties, such as Huang's Xiangsheng Pill, a famous doctor's ancestral classic formula. "Lixing" (doxorubicin hydrochloride liposome injection), which has mature domestic industrialization technology of innovative preparation liposomes, has formed an excellent product group of nearly 600 specifications.
Many products are inseparable from Jemincare's emphasis on quality and innovation. In terms of quality, the group has built large-scale modern production bases in Nanchang, Yichun, Wuxi and Hangzhou that meet GMP certification, invested heavily in the construction of Beijing Daxing R&D base, and built 14 research bases and 1 national postdoctoral workstation in Beijing, Wuxi, Hangzhou, Changzhou and other places. In terms of innovation, the Group has set up a pharmaceutical research institute in the United States, and in recent years, the cumulative investment in new drug research and development has reached 5% of the Group's sales, and has developed a number of international and domestic first-in-class original new drugs, laying a solid foundation for the internationalization and sustainable development of the pharmaceutical industry.
Looking forward to the future, Jemincare Group takes serving the country with industry and healthy people's livelihood as its responsibility, puts forward the strategic concept of "one core and two wings", takes "platform, capital, finance and internationalization" as the core, and Jinyuan and Pharmaceutical Industry Group as the two wings, promotes the industrial upgrading and transformation of the group, creates a new healthy development model, and is committed to becoming a leader in the big health industry that is highly respected.
